Anti-inflammatory drugs, antioxidants, and prostate cancer prevention
August 6th, 2009 Posted in prostate cancer preventionDamage to the prostate epithelium, triggers procarcinogenic inflammatory processes to promote disease development. The damaged epithelium may generate proliferative inflammatory atrophy (PIA) lesions, which may progress to prostatic intraepithelial neoplasia (PIN) or to prostate cancer.
To attenuate prostatic carcinogenesis generated by chronic or recurrent prostate inflammation, rational chemoprevention has thus far featured anti-inflammatory drugs and antioxidants. Results from clinical trials of these approaches pointed the need for mechanistic studies of the contribution of inflammation to prostatic carcinogenesis, more extensive analyses of the pharmacology, including distribution of drugs into target tissue, and, rational development of biomarkers to identify patients that are most likely to respond to anti-inflammatory drugs and antioxidants (targeted chemoprevention), alone, or in combination (combination chemoprevention).